Enhancing striatal acetylcholine facilitates dopamine release and striatal output in parkinsonian mice
Hongxia Li, Ziluo Chen, Yuyan Tan, Huoqing Luo, Chen Lu, Chao Gao, Xin Shen, Fang Cai, Ji Hu, Shengdi Chen · 2024
Read Enhancing striatal acetylcholine facilitates dopamine release and striatal output in parkinsonian mice by Hongxia Li, Ziluo Chen, Yuyan Tan, Huoqing Luo, Chen Lu, Chao Gao, Xin Shen, Fang Cai, Ji Hu, Shengdi Chen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11616140.txt.
Description
Hongxia Li and her nine co-authors, publishing in 2024, revisit a classic tug-of-war in the Parkinson's brain. The standard drug for the disease restores dopamine in a movement hub called the striatum. Another signal chemical there, acetylcholine, has long been cast as dopamine's opponent. Blocking it can ease symptoms. Yet boosting it also triggers dopamine release, which does not fit the rivalry story.
Using glowing sensors in mice with a Parkinson-like lesion, the team watched both chemicals live. The standard drug lowered acetylcholine. Dopamine did so through a defined chain of receptors and inhibitory cells. Restoring it during treatment squeezed out extra dopamine and strengthened movement circuits. It also improved the drug-induced turning behavior without worsening side-effect movements. The authors suggest fine-tuning this second signal could stretch the benefit of existing therapy.
Catalog record
| CREATOR | Hongxia Li, Ziluo Chen, Yuyan Tan, Huoqing Luo, Chen Lu, Chao Gao, Xin Shen, Fang Cai, Ji Hu, Shengdi Chen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |